Health&Life Co Ltd

Health&Life Co Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.31, well below the industry median of 0.65. The company holds TWD 150.22 million in cash and equivalents, representing 23.56% of total assets, and generates positive free cash flow of TWD 20.09 million. This liquidity position supports a current ratio of 1.62, indicating strong short-term solvency.

Profitability metrics show a return on equity of 4.09% and return on assets of 2.24%, both below the industry median of 6.8% and 4.1%, respectively. Operating income of TWD 1.59 million reflects a 0.79% margin, which is 40% below the sector average of 1.32%. Gross profit of TWD 34.84 million represents 17.32% of revenue, suggesting moderate pricing power.

The company operates as a single-segment entity with 100% revenue concentration in the domestic market. This geographic exposure creates a high concentration risk, as the firm lacks international diversification to buffer against local economic or regulatory shocks.

Recent financial performance shows a 12-month revenue decline of 4.2% to TWD 2.02 billion. Outlook for FY2024 indicates a 2.1% revenue contraction, with no material changes expected in FY2025. The company's capital expenditure of TWD -0.53 million suggests a maintenance capital strategy with no significant growth investments underway.

Risk assessment identifies low liquidity and dilution risk, with no immediate filing-based flags detected. The company's diluted shares outstanding remain unchanged at 47.41 million, and no recent equity issuance or ATM programs have been disclosed. However, the low ROE and ROA metrics suggest potential operational inefficiencies that could pressure future earnings.

Recent 10-K filings and earnings transcripts show no material changes in business strategy or risk profile. The last actual EPS of 0.59 TWD aligns with analyst expectations, but the 12-month EPS trend shows a 6.4% decline. No new product launches or major customer contracts have been disclosed in the past 90 days.

Return on equity of 4.1% outperforms the 1.4% cohort median, demonstrating efficient capital utilization.

Debt-to-equity ratio of 0.31 is below the 0.20 cohort median, suggesting a conservative leverage profile.

Low dilution and liquidity risks provide a stable financial foundation for ongoing operations.

Capex to revenue ratio sits in the top quartile, reflecting disciplined capital expenditure management.

Cash conversion ratio of 0.10 falls in the bottom quartile, indicating poor cash generation efficiency.